Enhancing care for people living with HIV: current and future monitoring approaches

References

• Smith CJ, Ryom L, Weber R, et al. D:A:D Study Group Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet. 2014;384:241–248.
   PubMed Web of Science ®Google Scholar
• Lee FJ, Amin J, Carr A. Efficacy of initial antiretroviral therapy for HIV-1 infection in adults: a systematic review and meta-analysis of 114 studies with up to 144 weeks’ follow-up. PLoS One. 2014;9(5):e97482. . eCollection 2014.
   PubMed Web of Science ®Google Scholar
• d’Arminio Monforte A, Cozzi-Lepri A, Di Biagio A, et al. Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting. J Antimicrob Chemother. 2019;74(5):1363–1367.
   PubMed Web of Science ®Google Scholar
• Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013;382(9903):1525–1533.
   PubMed Web of Science ®Google Scholar
• Kall M, Marcellin F, Harding R, et al. Patient-reported outcomes to enhance person-centred HIV care. Lancet HIV. 2019; pii: S2352-3018(19)30345-5. doi:10.1016/S2352-3018(19)30345-5.
   Web of Science ®Google Scholar
• De Maria A, Cossarizza A. CD4saurus Rex & HIVelociraptor vs. development of clinically useful immunological markers: a Jurassic tale of frozen evolution. J Transl Med. 2011;93(9):2011.
   Google Scholar
• Richman D, Crowe S, Harvey K. HIV viral load monitoring. Adv Exp Med Biol. 1999;458:199–212. Review.
   PubMed Web of Science ®Google Scholar
• Hanna GJ, D’Aquila RT. Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy. Clin Infect Dis. 2001;32(5): 774–782. Epub 2001 Feb 28. Review.
   PubMed Web of Science ®Google Scholar
• Siliciano JD, Siliciano RF. Recent trends in HIV-1 drug resistance. Curr Opin Virol. 2013;3(5):487–494. 2013 Sep 7. Epub Review.
   PubMed Web of Science ®Google Scholar
• Boukli N, Boyd A, Collot, et al. Utility of HIV-1 DNA genotype in determining antiretroviral resistance in patients with low or undetectable HIV RNA viral loads. J Antimicrob Chemother. 2018;73(11):3129–3136.
   PubMed Web of Science ®Google Scholar
• Margot N, Koontz D, McCallister S, et al. Measurement of plasma HIV-1 RNA below the limit of quantification (<20 copies/ml) of commercial assays with the integrase hiv rna single-copy assay. J Clin Virol. 2018;108:50–52.
   PubMed Web of Science ®Google Scholar
• Ryscavage P, Kelly S, Li JZ, et al. Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients. Antimicrob Agents Chemother. 2014;58(7):3585–3598.
   PubMed Web of Science ®Google Scholar
• Pernas B, Grandal M, Pertega S, et al. Any impact of blips and low-level viraemia episodes among HIV-infected patients with sustained virological suppression on ART? J Antimicrob Chemother. 2016;71(4):1051–1055.
   PubMed Web of Science ®Google Scholar
• Underwood M, Angelis K, Wang R, et al. Comparison of viral replication below 50 copies/mL for two-drug (DTG+RPV) versus three-drug current antiretroviral regimen (CAR) therapy in the SWORD-1 and SWORD-2 Studies. HIV Glasgow. 28–31 October 2018, Glasgow, United Kingdom. Abstract P311
   Google Scholar
• Underwood M, Urbaitye R, Man C, et al. HIV replication at <40 c/ml for dtg + 3tc vs dtg + tdf/ftc in the gemini-1 & −2 studies. croi 2019. Abstract 490.
   Google Scholar
• Tosiano MA, Jacobs JL, Shutt KA, et al. A simpler and more sensitive single-copy HIV-1 RNA assay for quantification of persistent HIV-1 Viremia in individuals on suppressive antiretroviral therapy. J Clin Microbiol. 2019;57(3):pii: e01714-18.
   PubMed Web of Science ®Google Scholar
• Rouzioux C, Trémeaux P, Avettand-Fenoël V. HIV DNA: a clinical marker of HIV reservoirs. Review Curr Opin HIV AIDS. 2018;135:389–394.
   PubMed Web of Science ®Google Scholar
• Kiselinova M, De Spiegelaere W, Buzon MJ, et al. Integrated and total HIV-1 DNA predict ex vivo viral outgrowth. PLoS Pathog. 2016;12(3):e1005472. eCollection 2016 Mar. Erratum in: PLoS Pathog. 2016;12(3):e1005532
   PubMed Web of Science ®Google Scholar
• Martinez-Picado J, Zurakowski R, Buzón MJ, et al. Episomal HIV-1 DNA and its relationship to other markers of HIV-1 persistence. Retrovirology. 2018;15(1):15. Review.
   PubMedGoogle Scholar
• Bruner KM, Wang Z, Simonetti FR, et al. A quantitative approach for measuring the reservoir of latent HIV-1 proviruses. Nature. 2019;566(7742):120–125.
   PubMed Web of Science ®Google Scholar
• Cillo AR, Hong F, Tsai A, et al. Blood biomarkers of expressed and inducible HIV-1. AIDS. 2018;32(6):699–708.
   PubMed Web of Science ®Google Scholar
• Anderson EM, Maldarelli F. The role of integration and clonal expansion in HIV infection: live long and prosper. Review Retrovirology. 2018;151:71.
   PubMedGoogle Scholar
• Pasternak AO, Berkhout B. What do we measure when we measure cell-associated HIV RNA. Retrovirology. 2018;151:13. Review.
   PubMedGoogle Scholar
• Casadellà M, Paredes R. Deep sequencing for HIV-1 clinical management. Virus Res. 2017;239:69–81. Review.
   PubMed Web of Science ®Google Scholar
• Cozzi-Lepri A, Noguera-Julian M, Di Giallonardo F, et al. CHAIN minority HIV-1 variants working group. low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing. J Antimicrob Chemother. 2015;70(3):930–940.
   PubMed Web of Science ®Google Scholar
• Pou C, Noguera-Julian M, Pérez-Álvarez S, et al. Improved prediction of salvage antiretroviral therapy outcomes using ultrasensitive HIV-1 drug resistance testing. Clin Infect Dis. 2014;59(4):578–588.
   PubMed Web of Science ®Google Scholar
• Rodriguez C, Nere ML, Demontant V, et al. Ultra-deep sequencing improves the detection of drug resistance in cellular DNA from HIV-infected patients on ART with suppressed viraemia. J Antimicrob Chemother. 2018;73(11):3122–3128.
   PubMed Web of Science ®Google Scholar
• Taylor T, Lee ER, Nykoluk M, et al. A MiSeq-HyDRA platform for enhanced HIV drug resistance genotyping and surveillance. Sci Rep. 2019;9(1):8970.
   PubMedGoogle Scholar
• Derache A, Iwuji CC, Baisley K, et al. Impact of next-generation sequencing defined human immunodeficiency virus pretreatment drug resistance on virological outcomes in the ANRS 12249 treatment-as-prevention trial. Clin Infect Dis. 2019;69(2):207–214.
   PubMed Web of Science ®Google Scholar
• MacArthur RD. Understanding HIV phenotypic resistance testing: usefulness in managing treatment-experienced patients. AIDS Rev. 2009;11(4): 223–230. Review.
   PubMed Web of Science ®Google Scholar
• Meybeck A, Alidjinou EK, Huleux T, et al. Virological outcome after choice of antiretroviral regimen guided by proviral HIV-1 DNA genotyping in a real-life cohort of HIV-Infected patients. AIDS Patient Care STDS. 2020;34(2):51–58.
   PubMed Web of Science ®Google Scholar
• Cannizzo ES, Bellistrì GM, Casabianca A, et al. Immunephenotype and function of CD38-expressing CD4+ and CD8+ T-cells in HIV-infected patients undergoing suppressive cART. J Infect Dis. 2015;211(9):1511–1513.
   PubMed Web of Science ®Google Scholar
• Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013;8(12):e81355.
   PubMed Web of Science ®Google Scholar
• Donaghy H, Pozniak A, Gazzard B, et al. Loss of blood CD11c(+) myeloid and CD11c(-) plasmacytoid dendritic cells in patients with HIV-1 infection correlates with HIV-1 RNA virus load. Blood. 2001;98:2574–2576.
   PubMed Web of Science ®Google Scholar
• Burdo TH, Lent MR, Autissier P, et al. Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after anti- retroviral therapy. J Infect Dis. 2011;204(1):154–163.
   PubMed Web of Science ®Google Scholar
• Srinivasa S, Fitch KV, Lo J, et al. Plaque burden in HIV-infected patients is associated with serum intestinal microbiota-generated trimethylamine. AIDS. 201;29:443–452.
   Google Scholar
• Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5(10):e203.
   PubMed Web of Science ®Google Scholar
• Peterson TE, Huppler Hullsiek K, Wyman Engen N, et al. INSIGHT START (Strategic Timing of AntiRetroviral Treatment) study group. Inflammation associates with impaired small arterial elasticity early in HIV disease. Open Forum Infect Dis. 2018;5(6):ofy117. 2018 Jun 1. eCollection.
   PubMed Web of Science ®Google Scholar
• Makgoeng SB, Bolanos RS, Jeon CY, et al. Markers of Immune Activation and Inflammation, and Non-Hodgkin Lymphoma: a meta-analysis of prospective studies. JNCI Cancer Spectr. 2018; 2(4):pky082. Review.
   PubMed Web of Science ®Google Scholar
• O’Brien MP, Zafar MU, Rodriguez JC, et al. Targeting thrombogenicity and inflammation in chronic HIV infection. Sci Adv. 2019;5(6):eaav5463.
   PubMed Web of Science ®Google Scholar
• Squillace N, Trabattoni D, Muscatello A, et al. Evaluation of adhesion molecules and immune parameters in HIV-infected patients treated with an atazanavir/ritonavir- compared with a lopinavir/ritonavir-based regimen. J Antimicrob Chemother. 2018;73(8):2162–2170.
   PubMed Web of Science ®Google Scholar
• Hosnijeh FS, Portengen L, Späth F, et al. Soluble B-cell activation marker of sCD27 and sCD30 and future risk of B-cell lymphomas: A nested case-control study and meta-analyses. Int J Cancer. 2016;138(10):2357–2367.
   PubMed Web of Science ®Google Scholar
• Falasca K, Reale M, Di Nicola M, et al. Circulating CD40 ligand, Dickkopf-1 and P-selectin in HIV-infected patients. HIV Med. 2019;20(10):681–690.
   PubMed Web of Science ®Google Scholar
• Ghiglione Y, Trifone C, Salido J, et al. PD-1 expression in HIV-specific CD8+ T cells before antiretroviral therapy is associated with HIV persistence. J Acquir Immune Defic Syndr. 2019;80(1):1–6.
   PubMed Web of Science ®Google Scholar
• Piconi S, Trabattoni D, Gori A, et al. Immune activation, apoptosis, and Treg activity are associated with persistently reduced CD4+ T-cell counts during antiretroviral therapy. AIDS. 2010;24(13):1991–2000.
   PubMed Web of Science ®Google Scholar
• Hattab S, Guiguet M, Carcelain G, et al. Soluble biomarkers of immune activation and inflammation in HIV infection: impact of 2 years of effective first-line combination antiretroviral therapy. HIV Med. 2015;16(9):553–562.
   PubMed Web of Science ®Google Scholar
• Xing Y, Shepherd N, Lan J, et al. MMPs/TIMPs imbalances in the peripheral blood and cerebrospinal fluid are associated with the pathogenesis of HIV-1-associated neurocognitive disorders. Brain Behav Immun. 2017;65:161–172.
   PubMed Web of Science ®Google Scholar
• von Sydow M, Sonnerborg A, Gaines H, et al. Interferon-alpha and tumor necrosis factor-alpha in serum of patients in various stages of HIV-1 infection. AIDS Res Hum Retroviruses. 1991;7:375–380.
   PubMed Web of Science ®Google Scholar
• Hagberg L, Cinque P, Gisslen M, et al. Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Res Ther. 2010;7:15.
   PubMed Web of Science ®Google Scholar
• Del Palacio M, Romero S, Casado JL. Proximal tubular renal dysfunction or damage in HIV-infected patients. AIDS Rev. 2012;14(3):179–187.
   PubMed Web of Science ®Google Scholar
• Ansari AW, Heiken H, Moenkemeyer M, et al. Dichotomous effects of C-C chemokines in HIV-1 pathogenesis. Immunol Lett. 2007;110(1):1–5.
   PubMed Web of Science ®Google Scholar
• Babu H, Sperk M, Ano TA, et al. Plasma metabolic signature and abnormalities in HIV-infected individuals on long-term successful antiretroviral therapy. Metabolites. 2019;9(10):210.
   Web of Science ®Google Scholar
• Knudsen B, Ertner G, Petersen J, et al. Plasma soluble CD163 level independently predicts all-cause mortality in HIV-1–infected individuals. J Infect Dis. 2016;214(8):1198–1204.
   PubMed Web of Science ®Google Scholar
• SubramanyaI V, McKay HS, Brusca RM, et al. Inflammatory biomarkers and subclinical carotid atherosclerosis in HIV-infected and HIV-uninfected men in the multicenter AIDS cohort study. PLoS One. 2019;14(4):e0214735.
   PubMed Web of Science ®Google Scholar
• Sutter K, Dickow J, Dittmer U. Interferon α subtypes in HIV infection. Cytokine Growth Factor Rev. 2018;40:13–18.
   PubMed Web of Science ®Google Scholar
• Tenorio AR, Zheng Y, Bosch RJ, et al. Soluble markers of inflammation and coagulation but Not T-Cell activation predict non–AIDS-DEFINING MORBID EVENTS DURING SUPPRESSIVE ANTIRETROVIRAL TREATMENt. JID. 2014;210:1248–1259.
   PubMed Web of Science ®Google Scholar
• Hunt PW, Cao HL, Muzoora C, et al. Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. AIDS. 2011;25:2123–2131.
   PubMed Web of Science ®Google Scholar
• Zungsontiporn N, Tello RR, Zhang G, et al. Non-classical monocytes and monocyte chemoattractant protein-1 (MCP-1) correlate with coronary artery calcium progression in chronically HIV-1 infected adults on stable antiretroviral therapy. PLoS One. 2016;11:2.
   Web of Science ®Google Scholar
• Lichtner M, Rossi R, Rizza MC, et al. Plasmacytoid dendritic cells count in antiretroviral-treated patients is predictive of HIV load control independent of CD4+ T-cell count. Curr HIV Res. 2008;6:19–27.
   PubMed Web of Science ®Google Scholar
• Moll M, Kuylenstierna C, Gonzalez VD, et al. Severe functional impairment and elevated PD-1 expression in CD1d-restricted NKT cells retained during chronic HIV-1 infection. Eur J Immunol. 2009;39(3):902–911.
   PubMed Web of Science ®Google Scholar
• Merlini E, Cerrone M, van Wilgenburg B, et al. Association Between Impaired Vα7.2+CD161++CD8+ (MAIT) and Vα7.2+CD161-CD8+ T-cell populations and gut dysbiosis in chronically HIV- and/or HCV-infected patients. Front Microbiol. 2019;10:1972.
   PubMed Web of Science ®Google Scholar
• Ahmad F, Hong HS, Jäckel M, et al. High frequencies of polyfunctional CD8 NK cells in chronic HIV-1 infection are associated with slower disease progression. J Virol. 2014;88(2):12397–12408. .
   PubMedGoogle Scholar
• Marchetti G, Cozzi-Lepri A, Merlini E, et al., Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count. AIDS. 25(11): 1385–1394. 2011. .
   PubMed Web of Science ®Google Scholar
• Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011;203(6):780–790. .
   PubMed Web of Science ®Google Scholar
• Lichtner M, Cicconi P, Vita S, et al., Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients. J Infect Dis. 211(2): 178–186. 2015.
   PubMed Web of Science ®Google Scholar
• Hodowanec AC, Lurain NS, Krishnan S, et al. Increased CMV IgG antibody Titer is associated with non-AIDS events among virologically suppressed HIV-positive persons. Pathog Immun. 2019;4(1):66–78.
   PubMedGoogle Scholar
• Serrano-Villar S, Sainz T, Lee SA, et al. HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog. 2014;10(5):e1004078.
   PubMed Web of Science ®Google Scholar
• Mussini C, Lorenzini P, Cozzi-Lepri A, et al., for the Icona Foundation Study Group. Incidence of CD4/CD8 ratio normalization and its role in the onset of non-AIDS related events in HIV-infected individuals achieving viral load suppression on cART: an observational cohort study. Lancet HIV. 2(3): e98–e106. 2015.
   PubMed Web of Science ®Google Scholar
• Trickey A, May MT, Schommers P, et al. Antiretroviral therapy cohort collaboration (ART-CC). CD4:CD8 ratio and CD8 count as prognostic markers for mortality in human immunodeficiency virus-infected patients on antiretroviral therapy: the antiretroviral therapy cohort collaboration (ART-CC). Clin Infect Dis. 2017;65(6):959–966.
   PubMed Web of Science ®Google Scholar
• Campbell LM, Fennema-Notestine C, Saloner R, et al. CHARTER Group. Use of neuroimaging to inform optimal neurocognitive criteria for detecting HIV-associated brain abnormalities. J Int Neuropsychol Soc. 2019;2:1–16.
   Google Scholar
• Antinori A, Di Biagio A, Marcotullio S, et al. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2016. New Microbiol. 2017;40(2):86–98.
   PubMed Web of Science ®Google Scholar
• Law MG, Friis-Moller N, El-Sadr WM, et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D study. HIV Med. 2006;7:218–230.
   PubMed Web of Science ®Google Scholar
• Crane HD et al. Optimal cardiovascular disease risk score for HIV. Conference on Retroviruses and Opportunistic Infections (CROI). February 22–25, 2016, Boston MA ( abstract 42).
   Google Scholar
• Taramasso L, Ricci E, Menzaghi B, et al., CISAI study group . weight gain: a possible side effect of all antiretrovirals. Open Forum Infect Dis. 2017;4(4): ofx239.
   PubMed Web of Science ®Google Scholar
• Bourgi K, Rebeiro PF, Turner M, et al. Greater weight gain in treatment naïve persons starting Dolutegravir-based antiretroviral therapy. Clin Infect Dis. 2019.
   Web of Science ®Google Scholar
• Bhagwat P, Ofotokun I, McComsey GA, et al. Changes in waist circumference in HIV-infected individuals initiating a raltegravir or protease inhibitor regimen: effects of sex and race. Open Forum Infect Dis. 2018;5(11):ofy201.
   PubMed Web of Science ®Google Scholar
• Nuvoli S, Caruana G, Babudieri S, et al. Body fat changes in HIV patients on highly active antiretroviral therapy (HAART): a longitudinal DEXA study. Eur Rev Med Pharmacol Sci. 2018;22(6):1852–1859.
   PubMed Web of Science ®Google Scholar
• Shaiykova A, Pasquet A, Goujard C, et al. Reduced bone mineral density among HIV-infected, virologically controlled young men: prevalence and associated factors. AIDS. 2018;32(18):2689–2696.
   PubMed Web of Science ®Google Scholar
• Milanini B, Paul R, Bahemana E, et al. AFRICOS study Team. Limitations of the International HIV Dementia scale in the current era. AIDS. 2018;32(17):2477–2483.
   PubMed Web of Science ®Google Scholar
• Trunfio M, Vai D, Montrucchio C, et al. Diagnostic accuracy of new and old cognitive screening tools for HIV-associated neurocognitive disorders. HIV Med. 2018;19:455–464.
   Web of Science ®Google Scholar
• 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary:a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation. 2019. Vol. 139:e1046–e1081.
   PubMed Web of Science ®Google Scholar
• Vlachopoulos C, Xaplanteris P, Aboyans V, et al. The role of vascular biomarkers for primary and secondary prevention. A position paper from the European society of cardiology working group on peripheral circulation: endorsed by the association for research into arterial structure and physiology (ARTERY) society. Atherosclerosis. 2015;241(2):507–532.
   PubMed Web of Science ®Google Scholar
• Singh P, Sharma P, Sahakyan KR, et al. Differential effects of leptin on adiponectin expression with weight gain versus obesity. Int J Obes (Lond). 2016;40(2):266–274.
   PubMed Web of Science ®Google Scholar
• Brown TT, Ross AC, Storer N, et al. Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens. Antivir Ther. 2011;16(7):1063–1072.
   PubMed Web of Science ®Google Scholar
• Segal E, Hassoun G, Maor C, et al. Quantitative ultrasonometry: an alternative and easy method to evaluate bone quality in people living with human immunodeficiency virus. J Musculoskelet Neuronal Interact. 2019;19(1):112–117.
   PubMed Web of Science ®Google Scholar
• Borderi M, Calza L, Colangeli V, et al. Prevalence of sub-clinical vertebral fractures in HIV-infected patients. New Microbiol. 2014;37(1):25–32.
   PubMed Web of Science ®Google Scholar
• McGinty T, Cotter AG, Sabin CA. HIV UPBEAT (understanding the pathology of bone diseases in HIV-infected subjects) study group. Assessment of trabecular bone score, an index of bone microarchitecture, in HIV positive and HIV negative persons within the HIV UPBEAT cohort. PLoS One. 2019;14(3):e0213440.
   Web of Science ®Google Scholar
• Güerri-Fernández R, Lerma-Chippirraz E, Fernandez Marron A, et al. Bone density, microarchitecture, and tissue quality after 1 year of treatment with tenofovir disoproxil fumarate. AIDS. 2018;32(7):913–920.
   PubMed Web of Science ®Google Scholar
• Rosca EC, Albarqouni L, Simu M. Montreal cognitive assessment (MoCA) for HIV-associated neurocognitive disorders. Neuropsychol Rev. 2019;29(3):313–327.
   PubMed Web of Science ®Google Scholar
• Gisslén M, Price RW, Andreasson U, et al. Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine. 2015;3:135–140.
   PubMed Web of Science ®Google Scholar
• EuroQol Group. EuroQol -a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199–208.
   PubMed Web of Science ®Google Scholar
• McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-item short-form health survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;31(3):247–263.
   PubMed Web of Science ®Google Scholar
• Smith KW, Avis NE, Mayer KH, et al. Use of the MQoL-HIV with asymptomatic HIV-positive patients. Qual Life Res. 1997;6(6):555–560.
   PubMed Web of Science ®Google Scholar
• AIDS clinical trials group outcomes committee ACTG. Quality of life 601–602. Health Survey Manual. 1999.
   Google Scholar
• Orlando Edelen MO, Thissen D, Teresi JA, et al. Identification of differential item functioning using item response theory and the likelihood based model comparison approach. Application to the mini-mental state examination. Med Care. 2006;44:S134–42.
   PubMed Web of Science ®Google Scholar
• Lavsa SM, Holzworth A, Ansani NT. Selection of a validated scale for measuring medication adherence. J Am Pharm Assoc. 2011;51(1):90–94.
   Google Scholar
• Justice AC, Holes W, Gifford AL, et al. Development and validation of a self-completed HIV symptom index. J Clin Epidemiol. 2001;54(1):577–590.
   Google Scholar
• Lewinsohn PM, Seeley JR, Roberts RE, et al. Center for epidemiologic studies depression scale (CES-D) as a screening instrument for depression among community-residing older adults. Psychol Aging. 1997;12(2):277–287.
   PubMed Web of Science ®Google Scholar
• Smyth C The Pittsburgh sleep quality index (PSQI. Best practices in nursing care to older adults. Issue number 6.1, revised 2012.
   Google Scholar
• Henrich G, Herschbach P. Questions on life satisfaction – a short questionnaire for assessing subjective quality of life. Eur J Psychol Assess. 2000;16(3):150–159.
   Web of Science ®Google Scholar
• Wiegel M, Meston C, Rosen R. The female sexual function index: cross validation and development of clinical cutoff scores. J Sex Marital Ther. 2005;31:1–20.
   PubMed Web of Science ®Google Scholar
• Holmes WC, Shen JA. Two approaches to measuring quality of live in HIV/AIDS population. HAT-QoL and MOS-HIV-. Qual Life Res. 1999;8:515–527.
   PubMed Web of Science ®Google Scholar
• Nelson E, Wasson J, Kirk J, et al. Assessment of function in routine clinical practice description of the COOP chart method and preliminary findings. J Chronic Dis. 1987;40(1):55S–69S.
   PubMedGoogle Scholar
• Ware E, Kosinski M, Keller SD. A 12-item short-form health construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220–233.
   PubMed Web of Science ®Google Scholar
• Wagner AC, Hart TA, McShane KE, et al. Health care provider attitudes and beliefs about people living with HIV: initial validation of the health care provider HIV/AIDS stigma scale (HPASS). AIDS Behav. 2014;12: 2937–408.
   Google Scholar
• Justice AC, Rabeneck L, Hays RD, et al. Sensitivity, specificity, reliability, and clinical validity of provider-reported symptoms: a comparison with self-reported symptoms. Outcomes committee of the AIDS clinical trials group. J Acquired Immune Defic Syndr. 1999;21(2):126–133.
   PubMed Web of Science ®Google Scholar
• Simpson KN, Hanson KA, Harding G, et al. Patient reported outcome instruments used in clinical trials of HIV-infected adults on NNRTI-based therapy: a 10-year review. Health Qual Life Outcomes. 2013;11:164.
   PubMed Web of Science ®Google Scholar
• Wilkins EL, Cohen CJ, Trottier B, et al. Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment. AIDS Care. 2016;28(3):401–408.
   PubMed Web of Science ®Google Scholar
• Wagner GJ, Goggin K, Remien RH, et al. A closer look at depression and its relationship to HIV antiretroviral adherence. Ann Behav Med. 2011;42(3):352–360.
   PubMed Web of Science ®Google Scholar
• Gay C, Portillo CJ, Kelly R, et al. Self-reported medication adherence and symptom experience in adults with HIV. J Assoc Nurses AIDS Care. 2011;22(4):257–268.
   PubMed Web of Science ®Google Scholar
• Glass TR, Geest S, Weber R, et al. Correlates of self-reported non adherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV cohort study. J Acquir Immune Defic Syndr. 2006;41(3):385–392.
   PubMed Web of Science ®Google Scholar
• Llibre JM, Hung CC, Brinson C, et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet. 2018;391(10123):839–849.
   PubMed Web of Science ®Google Scholar
• Li JZ, Sax PE, Marconi VC, et al. No significant changes to residual Viremia after switch to Dolutegravir and Lamivudine in a randomized trial. Open Forum Infect Dis. 2019;6(3):ofz056.
   PubMed Web of Science ®Google Scholar
• Cahn P, Madero JS, Arribas JR, et al. for the GEMINI Study Team. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet. 2019;393(10167):143–155.
   PubMed Web of Science ®Google Scholar
• Mills A, Garner W, Pozniak A, et al. Patient-reported symptoms over 48 weeks in a randomized, open-label, phase IIIb non-inferiority trial of adults with HIV switching to co-formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF versus continuation of non-nucleoside reverse Transcriptase inhibitor with Emtricitabine and Tenofovir DF. Patient. 2015;8(4):359–371.
   PubMedGoogle Scholar
• Gathe J, Arribas JR, Van Lunzen J, et al. Patient-reported symptoms over 48 weeks in a randomized, open-label, phase 3b non-inferiority trial of adults with HIV switching to coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF versus continuation of Ritonavir-boosted protease inhibitor with Emtricitabine and Tenofovir DF. Patient. 2015;8(5):445–454.
   PubMedGoogle Scholar
• Gallant J, Lazzarin A, Mills A, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017;390(10107):2063–2072.
   PubMed Web of Science ®Google Scholar
• Wohl D, Clarke A, Maggiolo F, et al. Patient-reported symptoms over 48 weeks among participants in randomized, double-blind, phase III non-inferiority trials of adults with HIV on co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus co-formulated Abacavir, Dolutegravir, and Lamivudine. Patient. 2018;11(5):561–573.
   PubMedGoogle Scholar
• Margolis DA, Gonzales-Garcia J, Stellbrink HJ, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017;390(10101):1499–1510.
   PubMed Web of Science ®Google Scholar
• Murray M, Antela A, Mills A, et al. Patient views on long-acting HIV Treatment: cabotegravir + Rilpivirine as maintenance therapy (ATLAS 48-week results). IAS. 2019;Mexico City. Mexico. Oral MOAB0103.
   Google Scholar
• Murray M, Bernal E, Chounta V, et al. Patient reported outcomes on long-acting cabotegravir + rilpivirine as maintenance therapy: FLAIR 48 week results. IAS. 2019; Mexico City. Mexico. Oral MOPEB258.
   Google Scholar
• Lifson AR, Grund B, Gardner EM, et al. Improved quality of life with immediate versus deferred initiation of antiretroviral therapy in early asymptomatic HIV infection. AIDS. 2017;31(7):953–963.
   PubMed Web of Science ®Google Scholar
• Boyce MB, Browne JP, Greenhalgh J. The experiences of professionals with using information from patient-reported outcome measures to improve the quality of healthcare: a systematic review of qualitative research. BMJ Qual Saf. 2014;23(6):508–518.
   PubMed Web of Science ®Google Scholar